RET and neoplasm: Testing for mismatch repair (MMR)/microsatellite instability (MSI), tumor mutational burden (TMB), NeuroTrophin Receptor Kinase (NTRK), and proto-oncogene tyrosine-protein kinase receptor (RET) can assist in identifying potential therapeutic targets for patients (3).